Increased Medication Error Analysis Is Key To Improving Drug Safety – Panel
This article was originally published in The Tan Sheet
Executive Summary
FDA should enhance its post-market monitoring of drug safety through greater surveillance of medication errors, a member of FDA's Drug Safety & Risk Management Advisory Committee said during a May 19 meeting in Silver Spring, Md